Ah, ok! Apologies for my misunderstanding, @ma420. Yes, I think...

Ah, ok! Apologies for my misunderstanding, @ma420. Yes, I think that could very well be a possibility.

I have a lot of confidence that we are only scratching the surface of what Zantrene can do clinically in the epitranscriptomic regulatory space. For those interested in developments outside of oncology, here is a paper I found very interesting that looked into how FTO expression changes in diabetic mice following a diabetes medication (1). I understand that using Zantrene in an acute setting (e.g. cancer) is preferred over something chronic (like diabetes), however, the findings make me wonder whether further inhibition of FTO could improve the efficacy of diabetes medications.

1 https://link.springer.com/article/10.1007/s13410-021-00974-0